ENVB
Enveric Biosciences, Inc.NASDAQHealthcare$1.99-1.97%ClosedMarket Cap: $1.2M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.51
P/S
0.00
EV/EBITDA
0.41
DCF Value
$12.33
FCF Yield
-685.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-255.4%
ROA
-172.1%
ROIC
-210.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-2.2M | $-2.2M | $-3.81 | — |
| FY 2025 | $0.00 | -Infinity% | $-8.8M | $-12.1M | $-36.24 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.9M | $-1.9M | $-10.81 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.5M | $-2.5M | $-11.64 | — |
| Q1 2025 | $0.00 | -Infinity% | $-2.2M | $-2.2M | $-14,584.44 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.2M | $-3.2M | $-57.84 | — |
| FY 2024 | $0.00 | -Infinity% | $-9.6M | $-9.6M | $-228.48 | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.1M | $-2.1M | $-17.76 | — |
| Q2 2024 | $0.00 | -Infinity% | $-1.9M | $-1.9M | $-16.08 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.5M | $-2.5M | $-21.00 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.4M | $-3.4M | $-33.51 | — |
| FY 2023 | $0.00 | -Infinity% | $-16.4M | $-17.3K | $-97.08 | — |